| Literature DB >> 31497032 |
You Zhou1,2,3, Xiao Zheng1,2,3, Bin Xu1,2,3, Wenwei Hu1, Tao Huang4, Jingting Jiang1,2,3.
Abstract
Ovarian cancer is one of the leading causes of cancer mortality in women. Since little clinical symptoms were shown in the early period of ovarian cancer, most patients were found in phases III-IV or with abdominal metastasis when diagnosed. The lack of effective early diagnosis biomarkers makes ovarian cancer difficult to screen. However, in essence, the fundamental problem is we know very little about the regulatory mechanisms during tumorigenesis of ovarian cancer. There are emerging regulatory factors, such as long noncoding RNAs (lncRNAs) and microRNAs (miRNAs), which have played important roles in cancers. Therefore, we analyzed the RNA-seq profiles of 407 ovarian cancer patients. An integrative network of 20,424 coding RNAs (mRNAs), 10,412 lncRNAs, and 742 miRNAs were construed with variance inflation factor (VIF) regression method. The mRNA-lncRNA-miRNA cliques were identified from the network and analyzed. Such promising cliques showed significant correlations with survival and stage of ovarian cancer and characterized the complex sponge regulatory mechanism, suggesting their contributions to tumorigenicity. Our results provided novel insights of the regulatory mechanisms among mRNAs, lncRNAs, and miRNAs and highlighted several promising regulators for ovarian cancer detection and treatment.Entities:
Keywords: functional regulator; mRNA–lncRNA–miRNA cliques; ovarian cancer; regulatory network construction; variance inflation factor regression
Year: 2019 PMID: 31497032 PMCID: PMC6712160 DOI: 10.3389/fgene.2019.00751
Source DB: PubMed Journal: Front Genet ISSN: 1664-8021 Impact factor: 4.599
Number of transcripts in expression data, constructed network, triplets of the 407 ovarian cancer patients.
| mRNA | lncRNA | miRNA | Total | |
|---|---|---|---|---|
|
| 20,462 | 10,419 | 742 | 31,623 |
|
| 16,667 | 4,796 | 207 | 21,670 |
|
| 633 | 1,184 | 169 | 1,986 |
Figure 1Flowchart of this study.
Figure 2Key mRNA–lncRNA–miRNA triplets on the integrative network of ovarian cancer. The red, green, and yellow nodes represented mRNA, lncRNA, and miRNA, respectively. Each mRNA–lncRNA–miRNA triplet formed a clique on the integrative network. The rectangle, triangle, and hexagon represented survival significant, cancer-stage significant, and both significant, respectively. In a clique of mRNA–lncRNA–miRNA, there were regulations between lncRNA and mRNA, miRNA and mRNA, and lncRNA and miRNA. The numbers on the edges were adjusted R2. (A) The mRNA–lncRNA–miRNA triplets of NFYA, RP11-401P9.4.1 and MIR600HG. (B) The mRNA–lncRNA–miRNA triplets of RBM5, RP11-401P9.4.1 and MIR600HG. (C) The mRNA–lncRNA–miRNA triplets of ALS2, RP11-401P9.4.1 and MIR600HG. (D) The mRNA–lncRNA–miRNA triplets of LAP3, RP11-401P9.4.1 and MIR600HG. (E) The mRNA–lncRNA–miRNA triplets of RAD52, RP11-401P9.4.1 and MIR600HG. (F) The mRNA–lncRNA–miRNA triplets of LUC7L, RP11-169K16.9.1 and MIR4519. (G) The mRNA–lncRNA–miRNA triplets of POLD3, RP11-736I10.1.1 and MIR130B. (H) The mRNA–lncRNA–miRNA triplets of POLD3, CTC-471C19.2.1 and MIR130B. (I) The mRNA–lncRNA–miRNA triplets of MTA1, RP11-492L8.2.1 and MIR218-1.
Figure 3Kaplan–Meier plots of the four RNAs associated with survival. The Kaplan–Meier plots of MIR600HG, MIR4519, POLD3, and MTA1 were shown in A, B, C, and D, respectively. (A) The high expression of MIR600HG was associated with high risk. (B) The low expression of MIR4519 was associated with high risk. (C) The low expression of POLD3 was associated with high risk. (D) The low expression of MTA1 was associated with high risk.
Figure 4Four-cliques that were both associated with survival and cancer stage. The red, green, and yellow nodes represented mRNA, lncRNA, and miRNA, respectively. The rectangle, triangle, and hexagon represented survival significant, cancer-stage significant, and both significant, respectively. (A) Four-cliques of CTD-2142D14.1.1, MIR124-3, CLPTM1L and NSUN2. (B) Four-cliques of RP11-318I4.1.1, MIR124-3, CLPTM1L and NSUN2. (C) Four-cliques of CTC-471C19.2.1, MIR130B, POLD3 and FAM168A. (D) Four-cliques of RP11-736I10.1.1, MIR130B, POLD3 and FAM168A. (E) Four-cliques of RP11-401P9.4.1, MIR600HG, KRIT1 and RAD52. (F) Four-cliques of RP11-401P9.4.1, MIR600HG, RBM5 and KRIT1. (G) Four-cliques of RP11-401P9.4.1, MIR600HG, NFYA and KRIT1. (H) Four-cliques of RP11-401P9.4.1, MIR600HG, KRIT1 and LAP3. (I) Four-cliques of RP11-401P9.4.1, MIR600HG, RBM5 and RAD52. (J) Four-cliques of RP11-401P9.4.1, MIR600HG, NFYA and RAD52. (K) Four-cliques of RP11-401P9.4.1, MIR600HG, LAP3 and RAD52. (L) Four-cliques of RP11-401P9.4.1, MIR600HG, ALS2 and RAD52. (M) Four-cliques of RP11-401P9.4.1, MIR600HG, RBM5 and ALS2. (N) Four-cliques of RP11-401P9.4.1, MIR600HG, RBM5 and DPM1. (O) Four-cliques of RP11-401P9.4.1, MIR600HG, NFYA and ALS2.
Figure 5Kaplan–Meier plot of CLPTM1L. The high expression of CLPTM1L was associated with high risk.